Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Feb 15, 2026; 17(2): 112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867
Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy
Yan Miao, Pan He, Lei Yan, Hui-Xia Cao, Feng-Min Shao, Department of Nephrology, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Zhengzhou 450003, Henan Province, China
Dan-Yu Wang, Department of Endocrinology, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Zhengzhou 450003, Henan Province, China
Author contributions: Miao Y initiated research; He P, Wang DY, Yan L, Cao HX designed the experiments and conducted clinical data collection, performed postoperative follow-up and recorded the data; Miao Y and Shao FM conducted the collation and statistical analysis, and wrote the original manuscript and revised the paper; all authors read and approved the final manuscript.
Supported by Major Public Welfare Projects in Henan Province, No. 201300310700; and Health Commission Project of Henan Province, No. SBGJ202301001.
Institutional review board statement: This study was approved by the Ethics Committee of Henan Provincial People's Hospital.
Informed consent statement: The Ethics Committee agrees to waive informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng-Min Shao, Department of Nephrology, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. shaofengmin123@163.com
Received: August 26, 2025
Revised: October 28, 2025
Accepted: December 11, 2025
Published online: February 15, 2026
Processing time: 164 Days and 0.8 Hours
Revised: October 28, 2025
Accepted: December 11, 2025
Published online: February 15, 2026
Processing time: 164 Days and 0.8 Hours
Core Tip
Core Tip: This retrospective study demonstrates that, in individuals with type 2 diabetes and nephropathy, the addition of semaglutide to canagliflozin monotherapy provides better renal protection and metabolic improvements compared to canagliflozin alone. The combination significantly reduced proteinuria, improved glycemic and lipid control, enhanced β-cell function, alleviated systemic inflammation and oxidative stress, without increasing adverse events. It offers an effective and safe intensification therapy option, particularly for those who have not achieved optimal levels of proteinuria or metabolic parameters under sodium-glucose cotransporter-2 inhibitor monotherapy.